Pharmacological Assistance Therapies for Arteriovenous Access Creation and Intervention for Dialysis Patients

Abstract

As the population that conducts hemodialysis using arteriovenous accesses increases, a lot of research and interest are increasing in creating and continuing arteriovenous accesses that maintain effective functions. Until now, many studies have been conducted on primary choice of treatment such as surgery or interventional procedures, and there are recommendations in the guidelines, but other pharmacological assistance therapies are still controversial. Prevention of early thrombosis, which is most commonly reported as early complications, this pharmacological assistance therapy has recently begun to be mentioned in the guidelines, but is still at the level of mentioning the possibility, and there is no mention of pharmacological assistance therapy for thrombotic occlusion or arteriovenous access stenosis, which are commonly reported as late complications. However, as the dialysis population grows and more attention is being paid to the management of arteriovenous access, studies are beginning to report on the pharmacological assistance therapy. Studies so far have shown that the use of antiplatelet agents in the formation of arteriovenous graft access may help prevent early thrombotic complications, but there is still insufficient evidence In lots of the studies so far have shown that the use of antiplatelet agents in the formation of arteriovenous graft access may help prevent early thrombotic complications, but sufficient evidence is still lacking. In addition, studies on pharmacological assistance therapy for late complications are still expected to require more research.